Jaume Pons compensation by year
ALX ONCOLOGY Summary Compensation Table · all 7 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $422,300 | $487,708 | $566,500 | $583,500 | $649,740 | $650,000 | $259,199 |
| Bonus | $0 | $500,000 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $848,780 | $521,540 | $950,400 | $0 |
| Option awards | $134,002 | $5,953,964 | $9,263,228 | $2,029,250 | $1,216,689 | $1,128,695 | $64,530 |
| Non-equity incentive | $147,900 | $292,759 | $283,250 | $272,786 | $357,357 | $288,860 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $0 | $0 | $0 | $0 | $0 | $0 | $650,000 |
| Total | $704,202 | $7,234,431 | $10,112,978 | $3,734,316 | $2,745,326 | $3,017,955 | $973,729 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ALX ONCOLOGY HOLDINGS INC DEF 14A filed April 20, 2026, accession 0001193125-26-163936, and prior-year filings.
How this page was built: the ALX ONCOLOGY HOLDINGS INC filed document, accession 0001193125-26-163936. Every figure is read from that document and cited to the page and table it appears in. Filed April 20, 2026.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 55,625 | $92,894 | — |
| RSU | 30,000 | $50,100 | — |
| RSU | 27,750 | $46,343 | — |
| RSU | 26,250 | $43,838 | — |
| Option | 75,209 | — | $15.84 |
| Option | 182,125 | — | $5.86 |
| Option | 96,584 | — | $11.47 |
| Option | 32,813 | — | $58.56 |
Per the Outstanding Equity Awards at Fiscal Year-End table in ALX ONCOLOGY HOLDINGS INC's FY2024 proxy; value at the fiscal year-end close, as the company printed it.
ALX ONCOLOGY’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Jason Lettmann | Chief Executive Officer | $2,470,844 |
| Harish Shantharam | Chief Financial Officer | $1,700,673 |
| Jaume Pons · this page | Former President and Chief Scientific Officer | $973,729 |
| Shelly Wong | Senior Vice President, Finance and Chief Accounting Officer | $940,405 |
Board service
ALX ONCOLOGY board · FY2021–FY2023How this board is paid
Company policy: ALX ONCOLOGY pays directors a $40,000 cash retainer. As stated in ALX ONCOLOGY's FY2023 proxy.
Jaume Pons's compensation dossier, ALX ONCOLOGY
You have read Jaume Pons's totals and holdings. The dossier adds each equity grant ALX ONCOLOGY disclosed for Jaume Pons and ALX ONCOLOGY's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full ALX ONCOLOGY compensation record
free company briefThis page is one person within ALX ONCOLOGY's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the ALX ONCOLOGY proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order ALX ONCOLOGY's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ALX ONCOLOGY's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.